Olaf Wendler1, Gerhard Schymik2, Hendrik Treede2, Helmut Baumgartner2, Nicolas Dumonteil2, Leo Ihlberg2, Franz-Josef Neumann2, Giuseppe Tarantini2, José Luis Zamarano2, Alec Vahanian2. 1. From King's Health Partners, London, UK (O.W.); Municipal Hospital, Karlsruhe, Germany (G.S.); University Heart Centre, Hamburg, Germany (H.T.); Department of Cardiovascular Medicine, University Hospital Muenster, Germany (H.B.); Clinique Pasteur, Toulouse, France (N.D.); University Central Hospital, Helsinki, Finland (L.I.); University Heart Centre, Bad Krozingen, Germany (F.-J.N.); University Padua, Department of Cardiac, Thoracic and Vascular Sciences, Italy (G.T.); University Hospital Ramon y Cajal, Madrid, Spain (J.L.Z.); and Hopital Bichat, Paris, France (A.V.). olaf.wendler@nhs.net. 2. From King's Health Partners, London, UK (O.W.); Municipal Hospital, Karlsruhe, Germany (G.S.); University Heart Centre, Hamburg, Germany (H.T.); Department of Cardiovascular Medicine, University Hospital Muenster, Germany (H.B.); Clinique Pasteur, Toulouse, France (N.D.); University Central Hospital, Helsinki, Finland (L.I.); University Heart Centre, Bad Krozingen, Germany (F.-J.N.); University Padua, Department of Cardiac, Thoracic and Vascular Sciences, Italy (G.T.); University Hospital Ramon y Cajal, Madrid, Spain (J.L.Z.); and Hopital Bichat, Paris, France (A.V.).
Abstract
BACKGROUND: The SOURCE 3 Registry (SAPIEN Aortic Bioprosthesis European Outcome) is a European multicenter, observational registry of the latest generation of transcatheter heart valve, the SAPIEN 3 (Edwards Lifesciences, Irvine, CA). Its purpose is to document outcomes of clinical safety and performance after European approval was given. METHODS: Here, we present the 30-day outcome of the SOURCE 3 Registry. All data are self-reported, and all participating centers have committed to support their consecutive experience with the SAPIEN 3 transcatheter heart valve, dependent on patient consent, before the start of the study. Adverse events are defined with Valve Academic Research Consortium 2 criteria and adjudicated by an independent clinical events committee. RESULTS: A total of 1950 patients from 80 centers in 10 countries were enrolled between July 2014 and October 2015. Of those, 1947 patients underwent transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 (mean age, 81.6±6.6 years; 48.1% female). Main comorbidities included coronary artery disease (51.5%), renal insufficiency (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logistic EuroSCORE of 18.3±13.2. Transfemoral access was used in 87.1% (n=1695); nontransfemoral, in 252 patients. Conscious sedation was used in 59.9% of transfemoral procedures, and in 50% of patients, TAVI was performed without aortic balloon valvuloplasty. Implantation success (1 valve in the intended location) was 98.3%. Conversion to conventional surgery (0.6%) and use of cardiopulmonary bypass (0.7%) were rare. Adverse events were low, with site-reported 30-day all-cause mortality of 2.2%, cardiovascular mortality of 1.1%, stroke of 1.4%, major vascular complications of 4.1%, life-threatening bleeding of 5%, and post-TAVI pacemaker implantation of 12%. Moderate or greater paravalvular regurgitation was observed in 3.1% of reporting patients. CONCLUSIONS: Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when this third-generation TAVI device is used.
BACKGROUND: The SOURCE 3 Registry (SAPIEN Aortic Bioprosthesis European Outcome) is a European multicenter, observational registry of the latest generation of transcatheter heart valve, the SAPIEN 3 (Edwards Lifesciences, Irvine, CA). Its purpose is to document outcomes of clinical safety and performance after European approval was given. METHODS: Here, we present the 30-day outcome of the SOURCE 3 Registry. All data are self-reported, and all participating centers have committed to support their consecutive experience with the SAPIEN 3 transcatheter heart valve, dependent on patient consent, before the start of the study. Adverse events are defined with Valve Academic Research Consortium 2 criteria and adjudicated by an independent clinical events committee. RESULTS: A total of 1950 patients from 80 centers in 10 countries were enrolled between July 2014 and October 2015. Of those, 1947 patients underwent transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 (mean age, 81.6±6.6 years; 48.1% female). Main comorbidities included coronary artery disease (51.5%), renal insufficiency (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logistic EuroSCORE of 18.3±13.2. Transfemoral access was used in 87.1% (n=1695); nontransfemoral, in 252 patients. Conscious sedation was used in 59.9% of transfemoral procedures, and in 50% of patients, TAVI was performed without aortic balloon valvuloplasty. Implantation success (1 valve in the intended location) was 98.3%. Conversion to conventional surgery (0.6%) and use of cardiopulmonary bypass (0.7%) were rare. Adverse events were low, with site-reported 30-day all-cause mortality of 2.2%, cardiovascular mortality of 1.1%, stroke of 1.4%, major vascular complications of 4.1%, life-threatening bleeding of 5%, and post-TAVI pacemaker implantation of 12%. Moderate or greater paravalvular regurgitation was observed in 3.1% of reporting patients. CONCLUSIONS: Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when this third-generation TAVI device is used.
Authors: Sara Fernandez-Santos; Alexis Théron; Philippe Pibarot; Frédéric Collart; Martine Gilard; Marina Urena; Tomas Hovorka; Philipp Kahlert; José Luis Zamorano Gomez Journal: Cardiol J Date: 2019-05-20 Impact factor: 2.737
Authors: Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Toby Rogers; Marvin H Eng; Gaetano Paone; Bradley G Leshnower; Mark Reisman; Lowell Satler; Ron Waksman; Marcus Y Chen; Annette M Stine; Xin Tian; Danny Dvir; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2019-06-12 Impact factor: 11.195
Authors: Hector Cubero-Gallego; Isaac Pascual; José Rozado; Ana Ayesta; Daniel Hernandez-Vaquero; Rocio Diaz; Alberto Alperi; Pablo Avanzas; Cesar Moris Journal: Ann Transl Med Date: 2019-10
Authors: Bruna Gomes; Maximilian Pilz; Christoph Reich; Florian Leuschner; Mathias Konstandin; Hugo A Katus; Benjamin Meder Journal: Clin Res Cardiol Date: 2020-06-24 Impact factor: 5.460